{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:48:04Z","timestamp":1790750884780,"version":"4.1.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Few studies of daily practice for patients with giant cell arteritis (GCA) are available. This French study aimed to describe the characteristics and management of GCA in a real-life setting.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Cross-sectional, non-interventional, multicenter study of patients \u226550 years old who consulted hospital-based specialists for GCA and were under treatment. Patient characteristics and journey, diagnostic methods and treatments were collected. Descriptive analyses were performed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, 306 patients (67% females, mean age 74 \u00b1 8 years old) were recruited by 69 physicians (internists: 85%, rheumatologists: 15%); 13% of patients had newly diagnosed GCA (diagnosis-to-visit interval &amp;lt;6 weeks). Overall median disease duration was 13 months (interquartile range 5\u201326). Most patients were referred by general practitioners (56%), then ophthalmologists (10%) and neurologists (7%). Most common comorbidities were hypertension (46%), psychiatric disorders (10%), dyslipidemia (12%), diabetes (9%), and osteoporosis (6%). Initial GCA presentations included cranial symptoms (89%), constitutional symptoms (74%), polymyalgia rheumatica (48%), and\/or other extra-cranial manifestations (35%). Overall, 85, 31, 26, and 30% of patients underwent temporal artery biopsy, high-resolution temporal artery Doppler ultrasonography, <jats:sup>18<\/jats:sup>FDG-PET, and aortic angio-CT, respectively. All patients received glucocorticoids, which were ongoing for 89%; 29% also received adjunct medication(s) (methotrexate: 19%, tocilizumab: 15%). A total of 40% had relapse(s); the median time to the first relapse was 10 months. Also, 37% had comorbidity(ies) related to or aggravated by glucocorticoids therapy.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This large observational study provides insight into current medical practices for GCA. More than one third of patients had comorbidities related to glucocorticoid therapy for a median disease duration of 13 months. Methotrexate and tocilizumab were the most common adjunct medications.<\/jats:p>","DOI":"10.3389\/fmed.2021.732934","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T05:55:52Z","timestamp":1636610152000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study)"],"prefix":"10.3389","volume":"8","author":[{"given":"Alfred","family":"Mahr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"de Boysson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Guerroui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"H\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Vinzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Broner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Lap\u00e9bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Sailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Zenone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Djerad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Jouvray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Shipley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Tieulie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Bouldoires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Idier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Paccalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3109\/03009742.2013.793777","article-title":"Occupational and socio-economic risk factors for giant cell arteritis: a nationwide study based on hospitalizations in Sweden","volume":"42","author":"Z\u00f6ller","year":"2013","journal-title":"Scand J Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B3","doi-asserted-by":"publisher","first-page":"ii32","DOI":"10.1093\/rheumatology\/kex424","article-title":"Large-vessel giant cell arteritis: diagnosis, monitoring and management","volume":"57","author":"Koster","year":"2018","journal-title":"Rheumatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3238\/arztebl.2013.0376","article-title":"The diagnosis and treatment of giant cell arteritis","volume":"110","author":"Ness","year":"2013","journal-title":"Dtsch Arztebl Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.revmed.2015.12.015","article-title":"Management of giant cell arteritis: recommendations of the French study group for large vessel vasculitis (GEFA)","volume":"37","author":"Bienvenu","year":"2016","journal-title":"Rev Med Interne."},{"key":"B6","unstructured":"Art\u00e9rite \u00e0 Cellules G\u00e9antes (Horton)2020"},{"key":"B7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice","volume":"77","author":"Dejaco","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/annrheumdis-2019-eular.2099","article-title":"Long-term outcome of tocilizumab of patients with giant cell arteritis. Results from part 2 of the GIACTA trial","volume":"78","author":"Stone","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/rheumatology\/kez251","article-title":"Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data","volume":"59","author":"Mahr","year":"2020","journal-title":"Rheumatology."},{"key":"B13","first-page":"57","article-title":"The different clinical patterns of giant cell arteritis","volume":"117","author":"De Boysson","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40744-018-0112-8","article-title":"Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK","volume":"5","author":"Gale","year":"2018","journal-title":"Rheumatol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3899\/jrheum.181127","article-title":"Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis","volume":"47","author":"Dumont","year":"2020","journal-title":"J Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/acr.23901","article-title":"Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis","volume":"72","author":"Mainbourg","year":"2019","journal-title":"Arthritis care & research."},{"key":"B17","doi-asserted-by":"publisher","first-page":"ii11","DOI":"10.1093\/rheumatology\/kex459","article-title":"Prevention of glucocorticoid morbidity in giant cell arteritis","volume":"57","author":"Buttgereit","year":"2018","journal-title":"Rheumatology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3899\/jrheum.140906","article-title":"Is statin exposure associated with occurrence or better outcome in giant cell arteritis? results from a French population-based study","volume":"42","author":"Pugnet","year":"2015","journal-title":"J Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.732934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T05:55:56Z","timestamp":1636610156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.732934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":18,"alternative-id":["10.3389\/fmed.2021.732934"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.732934","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"article-number":"732934"}}